What is Relamorelin?

A potent ghrelin-receptor agonist studied for diabetic gastroparesis and constipation through phase 2b/3.

Relamorelin in the library · Healing & Repair Peptides · Growth Hormone Secretagogues · Human Trials · What are peptides?

9 registered trials · 10 indexed papers · 3 human / 0 animal studies

From the PeptideWhiz library entry. "As described" sections summarize claims made in the sources; they are not PeptideWhiz endorsements.

What it is

Relamorelin is described as a pentapeptide ghrelin agonist developed to speed up stomach and bowel movement.

Mechanism (as described)

  • Activating ghrelin receptors in the gut increases motility; it also raises GH.

Evidence (as described)

  • Phase 2 trials reported faster gastric emptying and fewer vomiting episodes in diabetic gastroparesis (Lembo et al., 2016; Camilleri et al., 2017) and faster colonic transit in constipation (Acosta et al., 2015). Phase 3 development was discontinued.

Status

Investigational; development discontinued.

Registered human trials (9)

TrialPhaseStatusYearEnrolled
A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04Phase 3terminated2018450
A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03Phase 3terminated2018467
Study to Evaluate the Safety and Efficacy of Relamorelin in Participants With Diabetic Gastroparesis Study 02Phase 3terminated2018311
Diabetic Gastroparesis Study 05Phase 3terminated2018202
A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01Phase 3terminated2017336
Safety and Efficacy of Relamorelin Administered to Participants With Vomiting Symptoms and Moderate to Severe Diabetic GastroparesisPhase 2completed2015393
Effect of Relamorelin on Satiation, Gastric Volume, Gastric Accommodation and Distal Gastric Function in Healthy VolunteersPhase 1completed201516
Study to Evaluate the Effects of RM-131 in Patients With Chronic ConstipationPhase 1completed201418
A Phase 2 Study to Evaluate the Safety and Efficacy of RM-131 in Patients With Parkinson's Disease & Chronic ConstipationPhase 2terminated201318

Peer-reviewed studies (10)

PaperAuthorsJournalYearType
Overall safety of relamorelin in adults with diabetic gastroparesis: Analysis of phase 2a and 2b trial dataCamilleri M et al.Alimentary pharmacology & therapeutics2020Randomized Controlled Trial
Treatment With a Ghrelin Agonist in Outpatient Women With Anorexia Nervosa: A Randomized Clinical TrialFazeli PK et al.The Journal of clinical psychiatry2018Randomized Controlled Trial
Efficacy and Safety of Relamorelin in Diabetics With Symptoms of Gastroparesis: A Randomized, Placebo-Controlled StudyCamilleri M et al.Gastroenterology2017Randomized Controlled Trial
A randomized trial of relamorelin for constipation in Parkinson's disease (MOVE-PD): Trial results and lessons learnedParkinsonism & related disorders2017Randomized Controlled Trial
Effects of ghrelin receptor agonist, relamorelin, on gastric motor functions and satiation in healthy volunteersNelson AD et al.Neurogastroenterology and motility2016Randomized Controlled Trial
Relamorelin Reduces Vomiting Frequency and Severity and Accelerates Gastric Emptying in Adults With Diabetic GastroparesisLembo A et al.Gastroenterology2016Randomized Controlled Trial
Short-Term Effects of Relamorelin on Descending Colon Motility in Chronic Constipation: A Randomized, Controlled TrialAcosta A et al.Digestive diseases and sciences2016Randomized Controlled Trial
Relamorelin Relieves Constipation and Accelerates Colonic Transit in a Phase 2, Placebo-Controlled, Randomized TrialAcosta A et al.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2015Randomized Controlled Trial
The ghrelin agonist RM-131 accelerates gastric emptying of solids and reduces symptoms in patients with type 1 diabetes mellitusShin A et al.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2013Randomized Controlled Trial
Randomized controlled phase Ib study of ghrelin agonist, RM-131, in type 2 diabetic women with delayed gastric emptying: pharmacokinetics and pharmacodynamicsShin A et al.Diabetes care2013Randomized Controlled Trial

Conditions researched

Related compounds

FAQ

What is Relamorelin?

A potent ghrelin-receptor agonist studied for diabetic gastroparesis and constipation through phase 2b/3.

How many registered human trials study Relamorelin?

The PeptideWhiz trial index lists 9 registered trials for Relamorelin, the most recent from 2018.

How much published research exists on Relamorelin?

The PeptideWhiz paper index links 10 PubMed papers to Relamorelin; by study type, 3 human and 0 animal studies.

Which conditions is Relamorelin researched for?

Delayed gastric emptying on GLP-1 medicines, Insulin resistance, prediabetes & type 2 diabetes, Parkinson's disease.

Research and education only. Not medical advice. No dosing guidance. Data: ClinicalTrials.gov registry and PubMed via the PeptideWhiz index (204,289 studies).

Reported dosing ranges from research